Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

INTRODUCTION: Adoptive cell transfer of genetically engineered T cells is a promising treatment for malignancies; however, there are few ideal cancer antigens expressed on the cell surface, and the development of chimeric antigen receptor T cells (CAR-T cells) for solid tumour treatment has been slo...

Descripción completa

Detalles Bibliográficos
Autores principales: Okumura, Satoshi, Ishihara, Mikiya, Kiyota, Naomi, Yakushijin, Kimikazu, Takada, Kohichi, Kobayashi, Shinichiro, Ikeda, Hiroaki, Endo, Makoto, Kato, Koji, Kitano, Shigehisa, Matsumine, Akihiko, Nagata, Yasuhiro, Kageyama, Shinichi, Shiraishi, Taizo, Yamada, Tomomi, Horibe, Keizo, Takesako, Kazuto, Miwa, Hiroshi, Watanabe, Takashi, Miyahara, Yoshihiro, Shiku, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664294/
https://www.ncbi.nlm.nih.gov/pubmed/36375974
http://dx.doi.org/10.1136/bmjopen-2022-065109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664294/
https://www.ncbi.nlm.nih.gov/pubmed/36375974
http://dx.doi.org/10.1136/bmjopen-2022-065109

Ejemplares similares